Psyence Biomedical Ltd. issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably...
The firm is trying to advance its lead compound, REL-1017, through late-stage clinical trials. The post Relmada Therapeutics trims losses, slashes research...
Biotech company Seelos Therapeutics, Inc. (Nasdaq: SEEL) told investors on Tuesday that its drug SLS-005 (IV trehalose) failed a study to treat amyotrophic...
In a recent digital conversation with ex-CNN host Don Lemon, now shared widely across the internet, Tesla and SpaceX chief Elon Musk candidly discussed...
In a recent digital conversation with ex-CNN host Don Lemon, now shared widely across the internet, Tesla and SpaceX chief Elon Musk candidly discussed...
SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Cybin Inc. announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major...
TORONTO – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (‘Cybin’ or the ‘Company’), a clinical-stage biopharmaceutical company committed...
In a groundbreaking move, the Multidisciplinary Association for Psychedelic Studies (MAPS) has joined forces with Denver, marking a historic collaboration...